Caprion

Finding proteins that hit the mark

News

Caprion Pharmaceuticals Announces Biomarker Research Collaboration With Boehringer Ingelheim

Montreal, Canada - July 12, 2005 - Caprion Pharmaceuticals today announced a research collaboration with Boehringer Ingelheim to identify biomarkers of metabolic and inflammatory disease using Caprion's CellCartaTM proteomics discovery platform. Caprion will identify pharmacodynamic markers in plasma resulting from the administration of different pre-clinical pharmaceutical compounds.

"This collaboration represents yet another important disease biomarker discovery program for Caprion," noted Dr. Daniel Chelsky, Chief Scientific Officer of Caprion Pharmaceuticals. "This study reflects how Caprion's biomarker discovery capability addresses many key pharmaceutical needs, including predicting efficacy and safety and managing treatment progression."

In addition to this latest relationship, Caprion has in 2005 announced biomarker collaborations with leading biopharmaceutical companies to apply proteomics to more efficient and effective trial design. Other partners announced to date this year include Pfizer and Wyeth, who recently expanded their collaboration with Caprion to include applications in two clinical trials.

###

About Caprion Pharmaceuticals
Caprion is a leading proteomics-based drug discovery company applying CellCarta® to discover and develop innovative products for the diagnosis and treatment of disease. Caprion has established therapeutic antibody discovery partnerships with Abbott Laboratories (NYSE: ABT) and ICOS Corporation (NASDAQ: ICOS in Lung Cancer, and Biogen IDEC (NASDAQ: BIIB) in Colon Cancer, as well as pharmaco-proteomic discovery collaborations with Wyeth (NYSE: WYE), AstraZeneca (NYSE: AZN), Merck & Co (NYSE: MRK), and Pfizer (NYSE: PFE). Caprion's partners also include IDEXX Laboratories (NASDAQ: IDXX) and Ortho-Clinical Diagnostics (NYSE:JNJ). Caprion's therapeutic antibodies for the prevention of Hemolytic Uremic Syndrome (HUS) resulting from E. coli infection are currently in Phase I clinical trials. For more on Caprion, see www.caprion.com.

FOR MORE INFORMATION CONTACT:

Caprion Pharmaceuticals
Katherine Bonter
(514) 228-3624

Back to news list

© 2017 Caprion